Exhibitors Search
ATHEONBIO
| Exhibition | PARTNERING |
|---|---|
| Booth no. | E41 |
| Country | Korea, South |
| Address | 302 Galmachi-ro, Jungwon-gu, Seongnam-si, Gyeonggi-do, Republic of Korea |
| Tel (Rep.) | 031-750-0035 |
| Website | http://www.atheonbio.com |
Company Introduction
Atheon Bio, founded in 2022 in Korea, is a biotechnology company dedicated to developing next-generation antibody therapeutics for refractory solid tumors. Our research focuses on the tumor microenvironment (TME), where we have discovered a novel target overexpressed in tumor endothelial cells that is essential for angiogenesis and tumor progression. Our lead program, ATN001, is a first-in-class antibody that not only blocks tumor blood vessel growth but also reprograms the immune system, offering a differentiated mechanism to overcome both VEGF and PD-1 resistance. Preclinical studies in xenograft, syngeneic, and AMD models have demonstrated strong proof-of-concept efficacy. Building on this foundation, we are advancing a bispecific antibody pipeline, including PD-1/ATN001 for oncology and VEGF/ATN001 for ophthalmology indications such as wet AMD. Atheon Bio has received global recognition through the Johnson & Johnson QuickFire Challenge, and JP Morgan 2025 Global IR selection.
Promotional video
Exhibit Item
Next-Gen Bispecific Immunotherapy for Refractory Solid Tumors via TME Targeting
Exhibit Item Images
-
Product Name : next-generation bispecific antibody targeting novel tumor microenvironment (TME) for refractory solid tumors.Next-Gen Bispecific Immunotherapy for Refractory Solid Tumors via TME Targeting
Exhibit Description
The PD-1/ATN001 bispecific antibody combines checkpoint blockade with angiogenesis control, overcoming resistance in refractory solid tumors.
Co-Exhibitor or Partner’s Information
| Company Name | Country |
|---|---|
KYUNGYON EXHIBITION CORP.